Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Salvage-line of Capecitabine Plus Oxaliplatin Therapy (XELOX) for Patients With Inoperable/Advanced Gastric Cancer Resistant/Intolerant to Cisplatin (OGSG1403).
Sugimoto N, Kawada J, Oka Y, Ueda S, Murakami K, Nishikawa K, Kurokawa Y, Fujitani K, Kawakami H, Endo S, Sakai D, Shimokawa T, Satoh T. Sugimoto N, et al. Among authors: kurokawa y. Anticancer Res. 2025 Jan;45(1):307-313. doi: 10.21873/anticanres.17418. Anticancer Res. 2025. PMID: 39740851 Clinical Trial.
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study).
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, Kurokawa Y, Boku N, Terashima M, Yoshikawa T; Stomach Cancer Study Group of the Japan Clinical Oncology Group. Kita R, et al. Among authors: kurokawa y. Jpn J Clin Oncol. 2024 Dec 18:hyae174. doi: 10.1093/jjco/hyae174. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39690810
Authors' reply to 'RE: A real-world survey on expensive drugs used as first-line chemotherapy in patients with HER2-negative unresectable advanced/recurrent gastric cancer in the stomach cancer study group of the Japan clinical oncology group'.
Nishina T, Boku N, Kurokawa Y, Sasaki K, Machida R, Yoshikawa T. Nishina T, et al. Among authors: kurokawa y. Jpn J Clin Oncol. 2024 Nov 19:hyae149. doi: 10.1093/jjco/hyae149. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39558684 No abstract available.
Role of dedicated port cleaning devices in laparoscopic surgery.
Nagano S, Fujii S, Momose K, Yamashita K, Saito T, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kurokawa Y, Eguchi H, Doki Y, Nakajima K. Nagano S, et al. Among authors: kurokawa y. Surg Endosc. 2024 Dec;38(12):7613-7620. doi: 10.1007/s00464-024-11366-w. Epub 2024 Nov 11. Surg Endosc. 2024. PMID: 39528664 Free PMC article.
Short-term outcomes of a phase II trial of perioperative capecitabine plus oxaliplatin therapy for advanced gastric cancer with extensive lymph node metastases (OGSG1701).
Kimura Y, Sugimoto N, Endo S, Kawabata R, Matsuyama J, Takeno A, Nakamura M, Takeshita H, Satake H, Tamura S, Sakai D, Kawakami H, Kurokawa Y, Shimokawa T, Satoh T. Kimura Y, et al. Among authors: kurokawa y. Gastric Cancer. 2024 Nov 9. doi: 10.1007/s10120-024-01564-9. Online ahead of print. Gastric Cancer. 2024. PMID: 39520591
1,195 results